ProfileGDS5678 / 1449517_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 32% 33% 50% 43% 33% 32% 31% 33% 49% 30% 33% 34% 33% 32% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7644532
GSM967853U87-EV human glioblastoma xenograft - Control 22.7577633
GSM967854U87-EV human glioblastoma xenograft - Control 33.2089150
GSM967855U87-EV human glioblastoma xenograft - Control 42.9430543
GSM967856U87-EV human glioblastoma xenograft - Control 52.7019733
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.8032232
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.7664931
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.7297533
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.1627649
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.6599930
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.7370833
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.7381134
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.7465133
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.7271132